KSHN001034
Phase 1Small molecule
KSHN001034 is one of 21 small molecule programs targeting Female. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
23 competitors in Female
#DrugCompanyPhaseTrials
1Activella
Eli LillyPhase 3
Dostarlimab
IncytePhase 2
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 2
Sporanox
SSebela Pharmaceuticals Development LLC
Phase 1
Rifadin
SanofiPhase 1
Versed
CConrado Roberto Hoffmann Filho
Phase 1
Faslodex
FFresenius Kabi USA, LLC
Phase 1
Protonix
WWyeth-Lederle Vaccines
Phase 1
Isentress
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KSHN001034. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- KKashiv BioSciences, LLC